Technical Summary

• This technology relates to the compositions for treating or preventing metabolic diseases (i.e., diabetes and fatty liver) comprising a 4-hydroxy tamoxifen analogue and GSK5182, as an effective component.
• It has been confirmed through experiments that the GSK5182 substance functions to inhibit expression of glucogenic genes, reduce the blood glucose level and prevent the development of fatty liver.
• PK, medicinal effects in an animal test and a toxicity test have been completed.

Technical Superiority

Good treatment options for metabolic diseases with fewer side effects

• Therapeutic agents for treating diabetes including diabetes types I and II
• Excellent effects for improving diabetes
• It has been confirmed that there are no side effects even when the medicine is taken for an extended period of time.

Excellent anti-metabolic disease effects

• In vivo blood sugar-lowering effects
• In vivo anti-diabetes effects
• In vivo effect of inhibiting generation of glucose in the liver
• Confirmed effect of lower levels of liver damage markers GOT and GPT
• Preventing development of fatty liver (alcoholic and non-alcoholic)
• Completed verification regarding toxicity and side effects in human bodies

Various forms & preparations

• It can be processed into various types of preparations such as pharmaceutical compositions, food compositions and food additives
• It can be administered through various routes of administration such as intraperitoneally, intravenously, subcutaneously, intradermally and orally
  

Major Technical Data

Please see the flyer for further information about the in vivo tests.

Applications

• Oral preparations: solid and liquid preparations
• Parenteral preparations: injectable preparations, aqueous solutions, emulsions, lyophilized preparations, suppositories preparations
• Food compositions: Including all health foods in a conventional aspect